Back to search

Article

The FDA-approved drug Alectinib compromises SARS-CoV-2 nucleocapsid phosphorylation and inhibits viral infection in vitro

2020-08-14

Abstract excerpt

<h4>ABSTRACT</h4> While vaccines are vital for preventing COVID-19 infections, it is critical to develop new therapies to treat patients who become infected. Pharmacological targeting of a host factor required for viral replication can suppress viral spread with a low probability of viral mutation leading to resistance. In particular, host kinases are highly druggable targets and a number of conserved coronavirus...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
a58f4ccb-4a2a-5888-aac0-3e623f05a52a
DOI
10.1101/2020.08.14.251207
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
The FDA-approved drug Alectinib compromises SARS-CoV-2 nucleocapsid phosphorylation and inhibits viral infection in vitroDOI 10.1101/2020.08.14.251207
Select a neighboring publication to make it the new centre.